News
BerGenBio First half results 2025
BerGenBio ASA – Updated key information related to the rights issue
BerGenBio ASA: Approval of the merger plan and the fully underwritten rights issue
BerGenBio ASA: Notice of Extraordinary General Meeting
BerGenBio ASA – Key information related to the rights issue
Announcement of fully underwritten rights issue
BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue
BerGenBio ASA – Minutes from the annual general meeting 2025
BerGenBio ASA: Update on Strategic Review Process and Status of Activities